Literature DB >> 28918065

The role of epigenetics in lysosomal storage disorders: Uncharted territory.

Shahzeb Hassan1, Ellen Sidransky2, Nahid Tayebi1.   

Abstract

The study of the contribution of epigenetic mechanisms, including DNA methylation, histone modifications, and microRNAs, to human disease has enhanced our understanding of different cellular processes and diseased states, as well as the effect of environmental factors on phenotypic outcomes. Epigenetic studies may be particularly relevant in evaluating the clinical heterogeneity observed in monogenic disorders. The lysosomal storage disorders are Mendelian disorders characterized by a wide spectrum of associated phenotypes, ranging from neonatal presentations to symptoms that develop in late adulthood. Some lack a tight genotype/phenotype correlation. While epigenetics may explain some of the discordant phenotypes encountered in patients with the same lysosomal storage disorder, especially among patients sharing the same genotype, to date, few studies have focused on these mechanisms. We review three common epigenetic mechanisms, DNA methylation, histone modifications, and microRNAs, and highlight their applications to phenotypic variation and therapeutics. Three specific lysosomal storage diseases, Gaucher disease, Fabry disease, and Niemann-Pick type C disease are presented as prototypical disorders with vast clinical heterogeneity that may be impacted by epigenetics. Our goal is to motivate researchers to consider epigenetics as a mechanism to explain the complexities of biological functions and pathologies of these rare disorders.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Keywords:  DNA methylation; Epigenetics; Genotype/phenotype correlation; Histone modifications; Lysosomal storage disorders; microRNAs

Mesh:

Substances:

Year:  2017        PMID: 28918065     DOI: 10.1016/j.ymgme.2017.07.012

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  18 in total

Review 1.  Exploring genetic modifiers of Gaucher disease: The next horizon.

Authors:  Brad A Davidson; Shahzeb Hassan; Eric Joshua Garcia; Nahid Tayebi; Ellen Sidransky
Journal:  Hum Mutat       Date:  2018-09-11       Impact factor: 4.878

2.  A classic variant of Fabry disease in a family with the M296I late-onset variant.

Authors:  Shuma Hirashio; Reiko Kagawa; Go Tajima; Takao Masaki
Journal:  CEN Case Rep       Date:  2020-09-09

Review 3.  Lysosomal dysfunction in neurodegeneration: emerging concepts and methods.

Authors:  Vinod Udayar; Yu Chen; Ellen Sidransky; Ravi Jagasia
Journal:  Trends Neurosci       Date:  2022-01-13       Impact factor: 13.837

4.  Genetics provides new individualized therapeutic targets for Parkinson's disease.

Authors:  Eric Joshua Garcia; Ellen Sidransky
Journal:  Neural Regen Res       Date:  2021-05       Impact factor: 5.135

5.  A Quantitative Systems Pharmacology Model of Gaucher Disease Type 1 Provides Mechanistic Insight Into the Response to Substrate Reduction Therapy With Eliglustat.

Authors:  Ruth Abrams; Chanchala D Kaddi; Mengdi Tao; Randolph J Leiser; Giulia Simoni; Federico Reali; John Tolsma; Paul Jasper; Zachary van Rijn; Jing Li; Bradley Niesner; Jeffrey S Barrett; Luca Marchetti; M Judith Peterschmitt; Karim Azer; Susana Neves-Zaph
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2020-06-19

Review 6.  The third generation sequencing: the advanced approach to genetic diseases.

Authors:  Tiantian Xiao; Wenhao Zhou
Journal:  Transl Pediatr       Date:  2020-04

7.  Altered Gene Expression in Prefrontal Cortex of a Fabry Disease Mouse Model.

Authors:  Kai K Kummer; Theodora Kalpachidou; Miodrag Mitrić; Michiel Langeslag; Michaela Kress
Journal:  Front Mol Neurosci       Date:  2018-06-25       Impact factor: 5.639

Review 8.  Anderson-Fabry disease in heart failure.

Authors:  M M Akhtar; P M Elliott
Journal:  Biophys Rev       Date:  2018-06-16

9.  Clinical Diversity in Patients with Anderson-fabry Disease with the R301Q Mutation.

Authors:  Saori Yamamoto; Tasuku Nagasawa; Koichiro Sugimura; Atsuhiro Kanno; Shunsuke Tatebe; Tatsuo Aoki; Haruka Sato; Katsuya Kozu; Ryo Konno; Kotaro Nochioka; Kimio Satoh; Hiroaki Shimokawa
Journal:  Intern Med       Date:  2018-10-17       Impact factor: 1.271

10.  PRDX1 gene-related epi-cblC disease is a common type of inborn error of cobalamin metabolism with mono- or bi-allelic MMACHC epimutations.

Authors:  Catia Cavicchi; Abderrahim Oussalah; Silvia Falliano; Lorenzo Ferri; Alessia Gozzini; Serena Gasperini; Serena Motta; Miriam Rigoldi; Giancarlo Parenti; Albina Tummolo; Concetta Meli; Francesca Menni; Francesca Furlan; Marta Daniotti; Sabrina Malvagia; Giancarlo la Marca; Céline Chery; Pierre-Emmanuel Morange; David Tregouet; Maria Alice Donati; Renzo Guerrini; Jean-Louis Guéant; Amelia Morrone
Journal:  Clin Epigenetics       Date:  2021-07-02       Impact factor: 6.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.